SCHEMBL4263181

SCHEMBL4263181

Cc1c(-c2csc(-c3cccc(N)c3)n2)ccc2c1NC(=O)CO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.55
MAPT P10636 9/20 0.52
ALDH1A1 P00352 8/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
MAPK1 P28482 3/20 0.52
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.46
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.40
RECQL P46063 1/20 0.40
LMNA P02545 2/20 0.37
HTT P42858 2/20 0.37
MAP4K1 Q92918 1/20 0.37
CDK5 Q00535 3/20 0.37
CDK5R1 Q15078 3/20 0.37
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260398 0.88 NR3C2 (0.56) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4261993 0.87 NR3C2 (0.46) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4266653 0.86 POLB (0.48) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4262046 0.85 POLB (0.46) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4261043 0.84 POLB (0.49) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4258355 0.83 CYP17A1 (0.51) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4258380 0.82 POLB (0.51) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4265368 0.82 NR3C2 (0.48) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4266185 0.82 RAB9A (0.50) NR3C2MAPTALDH1A1MEN1KMT2A
SCHEMBL4267726 0.82 NR3C2 (0.46) NR3C2MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 NR3C2 7/4885MAPT 3273/4885ALDH1A1 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.